Toxicity Associated with Immune Checkpoint Inhibitors: Analysis of Immune-Related Adverse Events with a Pembrolizumab Biosimilar (Pembroria) - Fedyanin, M. Yu; Snegovoy, A. V.; Breder, V. V.; Linkova, Yu. N.; Zinkina-Orikhan, A. V.; Setkina, S. B.; Fogt, S. N.; Chistiakov, V. S.; Kravtsova, N. A. (Bezopasnostʹ i risk farmakoterapii (Online), 2023)
Keywords: biosimilar; clinical trials; immune-checkpoint inhibitors; immune-mediated adverse reactions; immune-related adverse events; immunotherapy; pd-1 inhibitor; pembrolizumab; pembroria